22-Dec-2025
No headlines found.
No press releases found.
No news found.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.
Grifols S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol GRFS.
As of December 22, 2025, GRFS stock price climbed to $9.08 with 467,814 million shares trading.
GRFS has a beta of 0.76, meaning it tends to be less sensitive to market movements. GRFS has a correlation of 0.18 to the broad based SPY ETF.
GRFS has a market cap of $6.18 billion. This is considered a Mid Cap stock.
In the last 3 years, GRFS traded as high as $12.15 and as low as $5.30.
The top ETF exchange traded funds that GRFS belongs to (by Net Assets): IBB, BINV, KOMP, SPDW, BSMC.
GRFS has outperformed the market in the last year with a price return of +19.9% while the SPY ETF gained +18.8%. However, in the short term, GRFS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -6.8% vs +3.5% return in SPY. But in the last 2 weeks, GRFS shares have fared better than the market returning +2.6% compared to SPY +0.2%.
GRFS support price is $8.84 and resistance is $9.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRFS shares will trade within this expected range on the day.
